Kymera Therapeutics Presents Preclinical Data Demonstrating Activity…

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 demonstrated combinatorial utility with the BCL-2 inhibitor venetoclax in the venetoclax-resistant AML model KT-253 is also active in other hematological malignancies, including DLBCL WATERTOWN, Mass., December 11, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. CYMR, a clinical-stage […]

Apellis announces 24-month phase 3 post hoc results demonstrating treatment…

Recent analyzes of microperimetry data showed positive trends for both monthly and bimonthly Pegcetacoplan treatment near the GA lesion margin compared to sham treatment These analyzes provide further evidence that slowing the growth of GA lesions with Pegcetacoplan has the potential to preserve visual function The data were presented during an oral presentation at the […]

X4 Pharma Highlights New Data Demonstrating Broad Potential Of Mavorixafor…

X4 Pharmaceuticals Inc XFOR new dates announced from its Phase 1b study evaluating the ability of its lead clinical candidate, mavorixafor, to increase absolute neutrophil count (ANC) in patients with chronic neutropenia (CN) as monotherapy or concomitantly with injectable granulocyte colony-stimulating factor (G-CSF). . People with CN have lower levels of neutrophils, a type […]